AllSides Balanced Search reveals information and ideas from all sides of the political spectrum so you can get the full picture.
Dec 08 2023
News
F.D.A. Approves Sickle Cell Treatments, Including One That Uses CRISPR
On Friday, the Food and Drug Administration approved the first gene editing therapy ever to be used in humans, for sickle cell disease, a debilitating blood disorder caused by a single mutated gene.
The agency also approved a second treatment using conventional gene therapy for sickle cell that does not use gene editing.
For the 100,000 Americans with the disease, most of them
New York Times (News)
Dec 08 2023
News
In historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell disease
The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.
The new medicine, called Casgevy, is made by Vertex Pharmaceuticals and CRISPR Therapeutics. Its authorization is a
STAT
Sep 16 2022
News
Crispr Gene-Editing Drugs Show Promise in Preliminary Study
Intellia Therapeutics Inc. reported encouraging early-stage study results for its Crispr gene-editing treatments, the latest sign that the pathbreaking technology could result in commercially available drugs in the coming years.
Intellia said Friday that one of its treatments, code-named NTLA-2002, significantly reduced levels of a protein that causes periodic attacks of swelling in six
Wall Street Journal (News)
Mar 03 2023
News
Ahead of genome summit in London, questions linger about CRISPR baby scandal
Next week, hundreds of scientists from around the world will convene in London for an international summit on genome editing. That technology, which enables scientists to easily excise, alter, or replace specific sections of DNA, was awarded the 2020 Nobel Prize for Chemistry.
STAT
Dec 08 2023
News
US FDA approves two gene therapies for sickle cell disease
The U.S. Food and Drug Administration (FDA) on Friday approved two gene therapies for sickle cell disease, making one of them the first treatment in the United States based on the Nobel Prize-winning CRISPR gene editing technology.
Casgevy, developed by partners Vertex Pharmaceuticals (VRTX.O) and CRISPR Therapeutics (CRSP.BN), and bluebird bio's (BLUE.O) Lyfgenia were approved for
Reuters
Oct 08 2020
News
Two women share chemistry Nobel in historic win for 'genetic scissors'
Two scientists have been awarded the 2020 Nobel Prize in Chemistry for developing the tools to edit DNA.
Emmanuelle Charpentier and Jennifer Doudna are the first two women to share the prize, which honours their work on the technology of genome editing.
Their discovery, known as Crispr-Cas9 "genetic scissors", is a way of making specific and precise changes to the DNA contained
BBC News
Mar 14 2020
Analysis
Biohackers Are on a Secret Hunt for the Coronavirus Vaccine
A collective of biohackers has begun circulating a document proposing a plan to create, test, and distribute a vaccine to battle SARS-CoV-2. To get started, they say they need "between $10-25k."
Reason's Zach Weissmueller sat down with the lead biologist on the project, who requested anonymity due to fear of retribution from the Food and Drug Administration (FDA). Reason has verified
Reason
Dec 08 2023
Headline Roundup
FDA Approves Gene Editing Treatment for Sickle Cell Disease
The Food and Drug Administration approved two gene therapy treatments for sickle cell disease.
For Context: Sickle cell is an inherited blood disease that causes organ failure, anemia, strokes and excruciating pain. The disease affects an estimated 100,000 Americans, most of whom are black, according to Reuters (Center bias).
Details: One of the approved treatments, called Exa-
New York Times (News)
Reuters
New York Post (News)